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Abstract.
Background: Early Alzheimer’s disease (AD) detection using cerebrospinal fluid (CSF) biomarkers has been recommended
as enrichment strategy for trials involving mild cognitive impairment (MCI) patients.
Objective: To model a prodromal AD trial for identifying MRI structural biomarkers to improve subject selection and to be
used as surrogate outcomes of disease progression.
Methods: APOE 4 specific CSF A42/P-tau cut-offs were used to identify MCI with prodromal AD (A42/P-tau positive)
in the WP5-PharmaCog (E-ADNI) cohort. Linear mixed models were performed 1) with baseline structural biomarker, time,
and biomarker × time interaction as factors to predict longitudinal changes in ADAS-cog13, 2) with A42/P-tau status, time,
and A42/P-tau status × time interaction as factors to explain the longitudinal changes in MRI measures, and 3) to compute
sample size estimation for a trial implemented with the selected biomarkers.
Results: Only baseline lateral ventricle volume was able to identify a subgroup of prodromal AD patients who declined faster
(interaction, p = 0.003). Lateral ventricle volume and medial temporal lobe measures were the biomarkers most sensitive to
disease progression (interaction, p≤ 0.042). Enrichment through ventricular volume reduced the sample size that a clinical
trial would require from 13 to 76%, depending on structural outcome variable. The biomarker needing the lowest sample
size was the hippocampal subfield GC-ML-DG (granule cells of molecular layer of the dentate gyrus) (n = 82 per arm to
demonstrate a 20% atrophy reduction).
Conclusion: MRI structural biomarkers can enrich prodromal AD with fast progressors and significantly decrease group size
in clinical trials of disease modifying drugs.
Keywords: Alzheimer’s disease, biomarkers, clinical trial, magnetic resonance imaging, mild cognitive impair-
ment, precision medicine
INTRODUCTION
Clinical trials of Alzheimer’s disease (AD) mod-
ifiers have invariably failed in the past 15 years
[1–3]. Failures have often been attributed to slow
disease progression in the placebo group, thus
greatly reducing the chance to detect a drug effect
in the treated group. Moreover, the standard out-
come used to assess global cognition in AD
clinical trials so far, is the Alzheimer’s Disease
Assessment Scale-Cognitive (ADAS-Cog) [4], quite
insensitive to mild progression in the early AD stages
[5, 6].
Neurodegeneration detected on magnetic reso-
nance imaging (MRI) is known to be a valuable
support for cohort enrichment [7–10] and to be more
sensitive to change than cognitive outcomes [11].
Structural MRI alterations similar to those found in
AD patients have been reported also in mild cogni-
tive impairment (MCI) patients [12–19]. However,
to the best of our knowledge, a systematic analysis
on imaging features that predict progression and their
relationship with AD pathological cerebrospinal fluid
(CSF) biomarkers in the MCI stage does not exist.
We studied a group of slowly progressing prodro-
mal AD patients and have examined a wide range
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of structural biomarkers to select the best ones to
improve prodromal AD trial design 1) by increas-
ing the homogeneity of the eligible population and 2)
by identifying reliable outcomes of disease progres-
sion. Prodromal AD patients were selected based on
APOE-specific CSF A42/P-tau cut-offs [35]. First,
we assessed the baseline structural biomarkers for
their ability in selecting patients who declined faster
within the A42/P-tau positive group. At the same
time, we longitudinally compared global and regional
neurodegeneration and white matter microstructural
alterations between A42/P-tau positive and nega-
tive aMCI patients in order to select biomarkers of
short term disease progression. Finally, we evaluated
the effect of the selected biomarkers on sample size
estimation.
MATERIALS AND METHODS
Study population
Data used in this study were obtained from
the European ADNI (E-ADNI) database, devel-
oped in workpackage 5 (WP5) of IMI PharmaCog
project (Innovative Medicine Initiative, http://www.
imi.europa.eu/content/pharma-cog) and stored on
the neuGRID platform (https://neugrid4you.eu/).
Between December 2011 and June 2013, 147 amnes-
tic mild cognitive impairment (aMCI) patients were
enrolled in 13 European memory clinics (see Gal-
luzzi et al. [20] for the complete list). Follow-up
examinations were performed every 6 months for 2
years or until patient progressed to clinical dementia
(follow-up was 20 ± 8 months, minimum: 6 months).
Inclusion and exclusion criteria have been described
in detail elsewhere [20]. Briefly, the main inclusion
criteria were age between 55 and 90 years; complaints
of memory loss by the patient or family relative,
and confirmed by family relative; Mini-Mental State
Examination (MMSE) [21] score of 24 and higher;
overall Clinical Dementia Rating [22] score of 0.5;
score on the logical memory test [23] lower than 1
standard deviation from the age-adjusted mean, 15-
item Geriatric Depression Scale [24] score of 5 or
lower, and absence of significant other neurologic,
systemic or psychiatric illness.
MRI processing
All MRI scans were performed on 3.0 Tesla
machines. MRI protocols were harmonized and
pipelines were optimized and described in detail
elsewhere [25–27]. Briefly, within-session T1 aver-
aging was performed and all structural images
were processed using the longitudinal pipeline of
FreeSurfer v6.0 to automatically generate subject-
specific cortical thickness and subcortical volume
[28–32]. The segmentation results were visually
inspected prior to the volume and thickness analy-
ses to confirm that no major errors had occurred.
No manual editing was performed. All FreeSurfer
analyses were performed on the neuGRID platform
(https://neugrid4you.eu/). Diffusion tensor imaging
(DTI) scans were preprocessed using DTIPrep tool
for automatic quality assurance, which included
motion and Eddy current correction for all subjects
[33]. The corrected data were then processed using
FSL for skull and nonbrain tissue removal (BET)
and to extract diffusion maps. White matter (WM)
regions-of-interest (ROIs) are predefined in the Johns
Hopkins University-ICBM-FA-1 mm atlas and were
backprojected with a nonlinear co-registration to each
subject’s diffusion maps on trackbased spatial statis-
tics (TBSS) space [34]. The analysis was focused on
ROI which are of relevance in MCI studies (Sup-
plementary Table 1). Left and right measures were
averaged for each subject.
Patients classification
Patients were dichotomized into A42/P-tau posi-
tive or negative based on baseline CSF A42/P-tau
level as well as APOE genotype. In particular,
A42/P-tau positivity was defined as ratio lower than
15.2 for APOE 4 carriers and 8.9 for non-carriers
as revealed by the mixture model analysis earlier
performed [35]. CSF and blood analysis have been
performed at the selected central site and described
elsewhere [20]. Briefly, A42, total tau (T-tau), and
P-tau were quantified in the CSF by ELISA kits
(Innogenetics, Belgium) according to the manufac-
turer’s instructions. Blood DNA was used for APOE
genotyping in a real-time polymerase chain reaction
(PCR) using dedicated TaqMan probes (Life Tech-
nologies, Carlsbad, CA, USA).
Statistical analysis
Statistical analyses were performed using SPSS for
descriptive statistics and R: A language and environ-
ment for statistical computing (version 3.4.1) [36].
Baseline participants characteristics were assessed by
parametric t-test (or corresponding non-parametric
Mann-Whitney) for continuous Gaussian (or
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Table 1
Model interpretation and exemplary MRI structural biomarkers selected based on LMM-2 results
LMM-2 outcome (Significant factors, p < 0.05) Model interpretation
Time × A42/P-tau status A42/P-tau positive and negative patients show biomarker differences already at
baseline. The biomarker progressed faster in positives compared to negatives.
Time
A42/P-tau status
Time × A42/P-tau status A42/P-tau positive and negative patients did not show biomarker differences at
baseline. The biomarker progressed faster in positives compared to negatives.
Time
Time × A42/P-tau status A42/P-tau positive and negative patients did not show biomarker differences at
baseline. The biomarker slowly progressed in positives only.
FA, fractional anisotropy; GC-ML-DG, granule cells in the molecular layer of the dentate gyrus.
non-Gaussian) distributed variables and by
Chi-square test for categorical data.
Two different types of Linear Mixed Models
(LMMs, performed by R-package lme4) were applied
with all available timepoints in A42/P-tau positive
patients only, to evaluate their sensitivity in picking-
up different cognitive trajectories (LMMs-1), and
in the whole MCI cohort, to select structural
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measures that progressed faster in A42/P-tau pos-
itive compared to negative patients (LMMs-2).
Random intercept and random slope were consid-
ered to account for individual differences at baseline
as well as for individual change over follow-up (see
details in Supplementary Methods 1). The output of
the LMMs were presented in terms of standardized 
coefficient, corresponding p-value and, for the inter-
action factor only, effect size (pseudo η2) calculated
as the ratio of explained variability of interaction
effect on total variability of each model.
LMMs-1 were conducted with baseline biomarker
measures, time and biomarker × time interaction as
covariates to predict cognitive decline measured as
longitudinal changes in ADAS-cog13 score. For
this model, volumes and thicknesses were obtained
from the cross-sectional processing of the baseline
T1 scans. Only A42/P-tau positive patients were
included. All models were adjusted for age, sex and
education. The distribution of the biomarker show-
ing the smallest p-value for the “biomarker × time
interaction” factor was tested for the presence of
components and cut-offs able to distinguish any sub-
groups. To this purpose, the mclust and flexmix
packages of R were applied in order to perform finite
mixture model [37, 38]. The estimation procedure
was carried out by Expectation-Maximization algo-
rithm [39], whereas the number of components and
the parametrization of each of them (i.e., the ‘best-
fit’ model) was chosen by the Bayesian Information
Criterion (BIC) indexes: lower indexes values indi-
cate best model [40]. The cut-off for distinguishing
components was defined as the biomarker value for
which the mixture model assigned equal probability
of belonging to two consecutive components.
LMMs-2 were conducted with time, group (corre-
sponding to CSF status), time × group interaction as
covariates. All models were further adjusted for age,
sex and baseline MMSE and volumes LMMs also
for total intracranial volume (TIV). Only biomark-
ers with significant group × time interaction were
reported, meaning that they differently progressed
over-time between groups (for detailed on model
interpretation refers to Table 1).
Finally, the effect of biomarkers-based enrichment
and end-points was assessed in the design of a 2-year
clinical trial of disease modifiers applying a sample
size calculation for linear mixed models with baseline
covariates [41]. Sample size was calculated for a 20
and 30% reduction of biomarker slope by fixing a
significant level for type I error equal to 0.05 and a
power of 0.8 for a two-sided test.
RESULTS
CSF quantification and APOE genotype were
available for 144 out of 147 aMCI patients of
Pharmacog/E-ADNI. The characteristics of these
subjects classified according to their baseline
A42/P-tau ratio value as well as APOE genotype
are shown in Table 2. A42/P-tau positive MCI
patients were similar for age, gender, and edu-
cation compared to negative patients but showed
worse global cognitive performance as measured
using MMSE (p = 0.006) and higher CSF T-tau levels
(p < 0.001).
Biomarkers sensitive to cognitive decline
Global cognition slightly improved in the A42/P-
tau negative patients and declined in the positive
group as indicated by a decrease and an increase
of the ADAS-cog13 score, respectively (time × CSF
status interaction effect, p < 0.001) (Fig. 1A). As in
prodromal AD trials only prodromal AD patients
are included, we evaluated the sensitivity of each
baseline structural biomarker to predict different
ADAS-cog13 trajectories within the A42/P-tau
positive group (LMMs-1). The analysis of the pro-
portion of variability in ADAScog13 score over
time explained by time, baseline biomarker values
and time × biomarker interaction reported a signifi-
cant interaction only for the lateral ventricle volume
(time × biomarker interaction, p = 0.003, standard-
ized = 0.287, η2 = 0.29). This means that high
or low values of the lateral ventricle volume were
able to predict different longitudinal ADAS-cog13
trajectories.
Mixture model was applied on the baseline lateral
ventricle volume (LVV) distribution of A42/P-tau
positive MCI patients to test for the existence of
subgroups. The analysis reported the presence of
2 subgroups (BIC for 2 component-model = 1645
compared to BIC = 1659 for the 1 component-model
and BIC = 1658 for the 3 component-model) and
one cut-off value of 14330 mm3 (Supplementary
Figure 1). Patients with large LVV (>14330 mm3)
were older (p = 0.006), mainly males (p = 0.006),
had higher education (p = 0.024) and showed worse
MMSE score (p = 0.024) compared to patients with
small LVV (<14330 mm3) (Table 3). According to
LMM1 results, subjects with large LVV declined
more rapidly on the ADAS-cog13 compared to those
with small LVV (Fig. 1B).
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Table 2
Clinical and socio-demographic features of aMCI patients stratified into A42/P-tau positive and negative
according to APOE4-specific cut-offs
A42/P-tau negative A42/P-tau positive pa
(n = 63) (n = 81)
Age, mean (SD) 68.3 (8.4) 69.8 (6.3) 0.208
Sex, F/M, No. 36/27 46/35 1.000
Education, mean (SD) 10.0 (4.3) 11.1 (4.4) 0.115
APOE 4 carriers, No. (%) 3 (5) 63 (78) <0.001
MMSE, mean (SD) 27.1 (1.8) 26.2 (1.8) 0.006
ADAS-cog13, mean (SD)b,c 19.1 (5.9) 21.6 (8.1) 0.052
CSF biomarkers, mean (SD, pg/ml)
A42 949 (244) 495 (132) <0.001
P-Tau 47 (15) 84 (38) <0.001
T-tau 301 (149) 614 (394) <0.001
aAssessed by ANOVA (for continuous Gaussian distributed variables) or Kruskall-Wallis with Dunn cor-
rection (for continuous non-Gaussian distributed variables) and Chi-square tests (for categorical variables).
bRange 0–85, with 0 as the best score. cInformation was missing for 1 patient. Values significant at the 5%
level are bold. ADAS-cog13, Alzheimer Disease Assessment Scale-Cognitive Subscale, version 13; A42,
amyloid-; APOE, apolipoprotein E; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination;
P-tau, tau phosphorylated at threonine 181; T-tau, total tau.
Fig. 1. Longitudinal ADAS-cog13 changes (A) in A42/P-Tau positive and negative MCI patients and (B) in the A42/P-Tau positive MCI
patients stratified according to LVV classification. Graphs illustrate the estimated values and 95% confidence intervals obtained from the
respective linear mixed models. Dotted line in (B) refers to ADAScog13 estimated values in the A42/P-Tau positive group. ADAScog13
range was 0–85, with higher score indicating worst performance. The ventricular volume cut-off was established by mixture model analysis
(Supplementary Figure 1).
Surrogate outcome of disease progression
Next, we examined the ability of each biomarker
in separating positive and negative aMCI patients to
identify those that progressed faster in the positive
group. Table 4 shows the proportion of variability in
MRI measures over time explained by time, A42/P-
tau status and time × A42/P-tau status interaction
(LMMs-2) for the biomarkers reporting a signif-
icant effect of the interaction. Volumes of lateral
ventricle, hippocampus and several its subfields,
amygdala as well as entorhinal thickness showed the
strongest association with disease progression in MCI
with prodromal AD (time × A42/P-tau status inter-
action, p < 0.042, –0.101< std < –0.032, 0.06< η2<
0.24). This means that the longitudinal course of the
structural measures is different in A42/P-tau positive
and negative MCI groups. For example, the model
regarding the lateral ventricle volume estimated that
A42/P-tau positive had an expansion of the volume
0.077 times higher than negative patients every six
months and thus, 0.308 times higher in 2 years. Con-
versely, a reduction of the GC-ML-DG (granule cells
of molecular layer of the dentate gyrus) volume was
6-monthly estimated 0.068 time higher (0.272 time
in 2 years) in positive compared to negative patients.
Of note, medial temporal lobe (MTL) regions were
atrophic already at baseline in A42/P-tau positive
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Table 3
Clinical and socio-demographic features of A42/P-tau positive MCI patients stratified
according to lateral ventricle volume (LVV)
Small LVV Large LVV pa
(n = 45) (n = 36)
Age, mean (SD) 68.1 (5.9) 71.9 (6.2) 0.006
Females, No. (%) 32 (71) 14 (39) 0.006
Education, mean (SD) 10.1 (4.0) 12.3 (4.6) 0.024
APOE 4 carriers, No. (%) 33 (73) 30 (83) 0.420
MMSE, mean (SD) 26.6 (1.9) 25.7 (1.7) 0.024
ADAS-cog13, mean (SD)b,c 20.2 (6.6) 23.3 (9.5) 0.091
CSF biomarkers, mean (SD, pg/ml)
A42 505 (139) 481 (123) 0.655
P-Tau 90 (43) 76 (29) 0.151
T-tau 669 (475) 545 (247) 0.398
aAssessed by ANOVA (for continuous Gaussian distributed variables) or Kruskall-Wallis with Dunn
correction (for continuous non-Gaussian distributed variables) and Chi-square tests (for categorical
variables). bRange 0–85, with 0 as the best score. cInformation was missing for 1 patient. Values
significant at the 5% level are bold. ADAS-cog13, Alzheimer Disease Assessment Scale-Cognitive
Subscale, version 13; A42, amyloid-; APOE, apolipoprotein E; CSF, cerebrospinal fluid; LVV,
lateral ventricle volume; MMSE, Mini-Mental State Examination; P-tau, tau phosphorylated at
threonine 181; T-tau, total tau.
compared with negative MCI patients (A42/P-tau
status, p < 0.004, –0.418< std < –0.248). Among
microstructural indexes, only fractional anisotropy
(FA) in the fornix showed a different longitudinal
alteration in MCI groups (time × A42/P-tau status
interaction, p = 0.007, std = 0.137, η2 = 0.09).
Surrogate outcomes for disease modifiers
The selected biomarkers of short term disease pro-
gression (listed in Table 4) were compared with
ADAS-cog13 in terms of sample size required to
observe a 20 and 30% treatment effect and power
of 0.8 (Table 5). Within the A42/P-tau MCI positive
group, to observe a 20% of treatment effect, mean-
ing a slope reduction of 20%, the ADAS-cog13 score
required 662 subjects per arm. Volumes were those
requiring the lower number of subjects and the hip-
pocampal volume was the best, needing 116 subjects.
Besides hippocampal volume, excellent performance
was found for two of its subfields, the GC-ML-DG
with 123 subjects and the molecular layer with 131
subjects.
Further gain in power was reached with almost all
biomarkers by selecting the A42/P-tau MCI pos-
itive with large LVV. Exception were: CA3 and
fimbria, which lost power; lateral ventricle, cere-
bral WM and istmus cingulate remained unaltered.
Again, to observe a reduction of 20% in slope, the
biomarker needing the lowest number of subjects is
the hippocampal subfield GC-ML-DG, 82, followed
by CA4, 83, and the hippocampal volume calculated
as sum of each subfield, 84.
DISCUSSION
In the PharmaCog/E-ADNI study, designed as a
clinical trial in the aMCI population, we examined a
wide range of structural and microstructural biomark-
ers known to be altered in MCI patients. The goal
was to select the best ones to improve prodromal AD
trial design 1) by increasing the homogeneity of the
eligible population and 2) by identifying reliable out-
comes of disease progression. Thus, we evaluated the
effect of the selected biomarkers in a 2-year clinical
trial involving A42/P-tau positive MCI patients with
a target of 20 or 30% slowing of disease atrophy treat-
ment effect and power of 0.8. Importantly, we did not
include the MCI population as a whole in our sample
size calculation or in the enrichment analysis as MCI
patient selection based on AD pathological biomark-
ers is the general practice in prodromal AD trial.
Consistently with recent evidence [8, 9, 42], we
found that the assessment of neurodegeneration on
MRI increased the statistical power of clinical trials
by reducing the sample size required when using CSF
cut-offs alone. Indeed, further selection of A42/P-
tau positive MCI patients by using the baseline LVV
classification reduced the sample size that a clinical
trial would require from 13 to 76%, depending on
the outcome considered. Moreover, we confirmed the
greater power of MRI measures to detect longitudi-
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Table 4
Ability of MRI structural biomarkers to separate CSF A42/p-tau Positive and Negative aMCI patients
Measure Time X A42/P-tau status Time A42/P-tau status
Std  p Effect size Std  p Std  p
Lateral Ventricle 0.077 <0.001 0.48 0.063 <0.001 0.112 0.216
GC-ML-DG –0.068 <0.001 0.24 –0.073 <0.001 –0.289 <0.001
Molecular layer HP –0.064 <0.001 0.24 –0.069 <0.001 –0.315 <0.001
CA4 –0.065 <0.001 0.22 –0.068 <0.001 –0.301 <0.001
Whole HP (subfields sum) –0.060 <0.001 0.21 –0.065 <0.001 –0.336 <0.001
Entorhinal –0.101 0.001 0.21 –0.043 0.010 –0.248 0.004
HP –0.069 <0.001 0.20 –0.083 <0.001 –0.307 <0.001
Subiculum –0.061 <0.001 0.18 –0.046 <0.001 –0.323 <0.001
Presubiculum –0.064 0.001 0.17 –0.048 <0.001 –0.281 <0.001
CA3 –0.050 0.004 0.14 –0.059 <0.001 –0.270 <0.001
Hippocampal tail –0.048 0.006 0.11 –0.064 <0.001 –0.418 <0.001
Isthmus cingulate –0.073 0.016 0.10 –0.042 0.012 –0.068 0.400
Temporal pole –0.065 0.010 0.09 –0.045 0.001 –0.076 0.400
Amygdala –0.048 0.007 0.09 –0.047 <0.001 –0.275 <0.001
FA fornix –0.137 0.007 0.09 –0.024 0.393 –0.118 0.153
Fimbria volume –0.070 0.043 0.08 –0.035 0.070 –0.147 0.055
Parahippocampal –0.059 0.039 0.07 –0.016 0.316 –0.133 0.135
CA1 –0.032 0.042 0.06 –0.059 <0.001 –0.259 <0.001
Cerebral WM –0.038 0.040 0.05 –0.078 <0.001 –0.093 0.138
CC Mid Anterior –0.141 0.045 0.05 0.026 0.497 –0.088 0.303
Linear mixed models for volume analyses included age, sex, baseline MMSE, TIV, time, A42/P-tau status, time × A42/P-tau status
interaction as predictors. Linear mixed models for thickness and DTI parameter analyses included age, sex, baseline MMSE, time, A42/P-
tau status, time × A42/P-tau status interaction as predictors. Only biomarkers with significant Time × A42/P-tau status interaction effect
(p < 0.05) are shown. Values significant at the 5% level are bold. CA, Cornu Ammonis; CC, corpus callosum; FA, fractional anisotropy;
GC-ML-DG, Granule cells in the molecular layer of the dentate gyrus; HP, hippocampus; Std, Standardized; WM, white matter.
nal changes compared to ADAScog13 [11, 43–45].
The presented results show that hippocampus is the
region most sensitive to disease progression and
confirms its feasibility to be used as surrogate out-
come for a clinical trial of disease modifiers in MCI
with prodromal AD. In A42/P-tau positive MCI
patients considered as a whole, the most significant
gain of power was obtained by using the hippocampal
volume. When combined enrichment was applied, the
biomarkers needing the smallest sample size was the
hippocampal subfield GC-ML-DG that would require
82 subjects compared to ADAScog13 and hippocam-
pal volume needing 364 and 87 subjects, respectively.
Compared to previous reports focused on multi-
biomarker enrichment, we applied a data driven
approach to select the best biomarker for cohort
enrichment. Among all the biomarkers found altered
in the MCI stage we investigated, the linear mixed
model showed that only LVV was sensitive in pick-
ing up different ADAScog13 trajectories within
the A42/P-tau positive MCI patients. We expected
to find a similar association between baseline
hippocampal volume, to date the only qualified
biomarker for enrichment of clinical trials in pre-
dementia stages of AD [10], and ADAScog13
progression but, surprisingly, we did not. Previous
findings demonstrated that baseline LVV exami-
nation improved risk prediction in MCI patients
[46] and reduced sample size in AD clinical
trials better than MTL measures [47–49]. Moreover,
a stronger correlation with changes on cognitive tests
was reported for LVV enlargement compared with
hippocampal atrophy rates [48]. In patients with
MCI, this association has previously been observed
in APOE 4 carriers only [43] who were overrep-
resented in the prodromal AD group of the present
study. The higher sensitivity of LVV compared to
MTL regions in predicting different cognitive decline
within the A42/P-tau positive MCI patients may
be related to methodological and biological issues.
Hence, considering that a large portion of the ventri-
cle is adjacent to MTL regions, LVV likely reflects the
AD-related atrophy that occur in this region in the pre-
clinical stages of dementia [50, 51] and, conversely to
hippocampus, measurement is more robust and less
prone to segmentation errors giving the sharp contrast
between the signal intensity of CSF in the ventri-
cles and surrounding tissue in T1-weighted MRI
images. Furthermore, LVV may also reflects atrophy
in other regions than the MTL and likely represents a
global measure of neurodegeneration as whole-brain
volume, which correlates with clinical progression
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Table 5
Sample size estimates required in each arm of a placebo-controlled trial in A42/P-tau positive
MCI patients to observe 20% and 30% atrophy reduction of brain structural outcomes
A42/P-tau positive (n/arm) Sample size
All With large LVV reduction
20% 30% 20% 30% %
ADAS-Cog13 662 294 364 162 –45
Lateral Ventricle 193 86 182 81 –6
GC-ML-DG 123 55 82 36 –33
Molecular layer HP 131 58 90 40 –31
CA4 133 59 83 37 –37
Whole HP (subfields sum) 141 63 84 37 –41
Entorhinal 407 181 285 126 –30
HP 116 52 87 39 –25
Subiculum 237 105 196 87 –17
Presubiculum 266 118 135 60 –49
CA3 227 101 259 115 14
Hippocampal tail 236 105 162 72 –31
Isthmus cingulate 544 242 553 247 2
Temporal pole 508 226 324 144 –36
Amygdala 364 162 87 39 –76
FA fornix 749 333 497 221 –13
Fimbria volume 1077 479 1941 863 80
Parahippocampal 1446 643 400 178 –72
CA1 269 120 170 76 –37
Cerebral WM 168 75 164 73 –2
CC Mid Anterior 6769 3009 1742 774 –74
Sample size calculations are based on linear mixed models performed in all A42/P-Tau positive patients and in
those with large baseline lateral ventricle volume assuming a 20, 30% slope reduction of the outcome in a 2-year
trial with scans every six months. All calculations were performed by fixing significant level of type I error of
0.05, power equal to 0.8 and not controlling for normal aging. The ventricular volume cut-off was established by
mixture model analysis (Supplementary Figure 1). ADAS-cog13, Alzheimer Disease Assessment Scale-Cognitive
Subscale, version 13; CA, Cornu Ammonis; FA, fractional anisotropy; GC-ML-DG, Granule cells in the molecular
layer of the dentate gyrus; HP, hippocampus; LVV, lateral ventricle volume; WM, white matter.
[48, 52, 53]. A more intriguing and less investigated
scenario considers ventricular dilation as a marker
of altered CSF dynamics and a biological proxy
for faulty CSF clearance mechanisms in AD [54].
Failure of the CSF to clear potentially toxic metabo-
lites would lead to accumulation of A42, P-tau, and
perhaps other toxins in the brain and thus, may have
a role in the onset and progression of AD [55, 56].
This would give a plausible biological explanation
on the reason why aMCI patients with prodromal
AD and with large LVV showed faster cognitive
decline compared to those with small LVV. Moreover,
it suggests that, when the CSF AD biomarkers are
present at pathological levels, LVV may be a valuable
biomarker to distinguish fast and slow decliners.
Our 2-year longitudinal analysis reported the
strongest association between baseline CSF patho-
logical values and progressive deterioration in key
AD regions such as hippocampus, several of its
subfields and entorhinal cortex. Although these struc-
tural abnormalities have been extensively reported in
aMCI and AD patients, to the best of our knowledge,
no one has investigated their longitudinal changes
in aMCI patients as a function of CSF pathology.
Besides grey matter atrophy, prodromal AD patients
exhibited also a slightly progressive WM degener-
ation as indicated by WM shrinkage at global level
and in the middle/anterior portion of the corpus callo-
sum. Moreover, MRI diffusion revealed a progressive
structural connectivity reduction in the fornix, impor-
tant for episodic memory recall [57], which is in line
with progressive involvement of the posterior mesio-
temporal network in prodromal AD [58], especially
as a change in FA of the fornix did not differ in
A42/P-tau positive and negative patients at baseline,
but progressed slowly in positives only.
Demonstration of disease-modifying therapies
efficacy is garnered through clinical trial designs
and biomarkers [59]. Enhanced disease understand-
ing can be translated into better clinical trial design
by increasing the chance to enroll individuals who
have a higher probability to positively respond to
drugs (and reducing the adverse events) and by iden-
tifying those markers most likely to be sensitive to
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pharmacological manipulation. Moreover, in the AD
field, where no effective treatment is available at the
moment, selective enrolment applying CSF A42 and
P-tau biomarkers as well as APOE genotype can be
applied for testing innovative treatments targeting
not only amyloid but also tangles or APOE-related
phenomena.
The main limitation of the study is the lack of a
healthy control group. We did not consider the effect
of structural changes due to normal aging in our sam-
ple size calculation. Similarly, we did not account for
other important variables impacting the efficiency of
clinical trials, such as participants drop out or screen-
ing failure rates. Thus, a real trial would likely involve
a larger number of participants than reported in the
present study. Secondly, the study is limited by the
absence of the validation in an independent popula-
tion, but the purpose here was to investigate a typical
clinical trial population. We provided initial evidence
of the benefit that LVV based enrichment could have.
However, further investigations to confirm the LVV
sensitivity in identifying fast decliners in MCI with
prodromal AD are needed.
In conclusion, the selection of homogeneous aMCI
patients using a multi-biomarker strategy enables
to test the efficacy of new drugs in prodromal AD
trial in relatively small groups of mildly progressing
patients. Baseline lateral ventricular volume was the
best biomarker to be used for cohort enrichment and
volume of the GC-ML-DG hippocampal subfield was
the ideal outcome measure when considering trials of
MCI population enriched for CSF AD biomarker.
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